AbolerIS Pharma

AbolerIS Pharma

Foundation date

28/11/2019

Sector

#Biotechnology - Therapeutics

Subsector

• #Therapeutics - Cell therapy

Therapeutic areas

• #Diseases of the blood and blood-forming organs - immune disorders

AbolerIS Pharma aims to develop novel and unique therapeutic approaches to induce immune tolerance and preserves useful immune responses in inflammatory, autoimmune and degenerative diseases.

Anti-CD45RC monoclonal antibody to deplete effector T cells and preserve regulatory and memory T cells.

IL-34 cytokine to induce tolerogenic macrophages/DCs and regulatory T cells.

Founded by a team with a long cutting-edge translational expertise in regulatory T cells and mechanisms of tolerance.